Calliditas Therapeutics CALT
This picture changes. Follow Calliditas Therapeutics free — email when the signal or risk changes + a Sunday weekly brief.
Follow Calliditas Therapeutics freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 6 Apr 2026
Latest news check: 20 Jul 2026
General analysis — not personal advice.
NEUTRAL
8/10
Confidence
If you want exposure: consider Asahi Kasei (3407 JP) instead.
The equity is acquired/delisted, making direct investment difficult or impossible for many investors.
- Exposure to the assets is effectively via Asahi Kasei.
- Key value drivers are setanaxib data and continued TARPEYO growth, but transparency may be lower post-acquisition.
Market sentiment
6/10
→
Trend: Stable
Sentiment is cautiously positive around TARPEYO’s commercial potential, but discussion has faded post-delisting; attention is mainly on pipeline readouts and Asahi Kasei’s execution.
Risk assessment
6/10
Dilution:
Low
Private subsidiary with parent-company support
Jurisdiction:
Low
Operations mainly in US/EU/Sweden
Execution:
Medium
Commercial scale-up and clinical trials remain
About the company
Calliditas Therapeutics is a biopharma company focused on rare kidney diseases, with the commercial product TARPEYO/Kinpeygo (delayed-release budesonide) for IgA nephropathy. The company was acquired by Asahi Kasei in 2024 and delisted from Nasdaq Stockholm, meaning reporting and tradability may be limited or consolidated into the parent company.
Sector:
Biotech and orphan drugs (kidney diseases)
Type:
Biotech
Next report
14 Aug 2026
Q2
Horizon:
Bull case
Strong commercial momentum for TARPEYO following full approvals (US/EU).
- Pipeline updates (setanaxib) could improve the upside case.
- Asahi Kasei backing may reduce funding concerns and improve execution.
Bear case
Delisting/information gap may reduce transparency and liquidity.
- IgAN competition could pressure growth and pricing.
- Clinical risk: negative signals/delays in the setanaxib program.
Signal rationale (informational)
The equity is acquired/delisted, making direct investment difficult or impossible for many investors.
- Exposure to the assets is effectively via Asahi Kasei.
- Key value drivers are setanaxib data and continued TARPEYO growth, but transparency may be lower post-acquisition.
Recent news
- Asahi Kasei presented its One Pharma strategy at the BIO International Convention in June 2026 highlighting Calliditas integration. Novartis received full FDA approval for Fabhalta in July 2026 intensifying competition for Tarpeyo in the US market.
Exchange
NASDAQ
Type
Biotech
Sector
Biotech and orphan drugs (kidney diseases)
This picture changes. Follow Calliditas Therapeutics free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.